Nexalin Technology (NXL) Change in Receivables (2021 - 2026)
Nexalin Technology (NXL) posted Change in Receivables of -$27886.0 for Q2 2026, down 3593.51% on a QoQ basis from -$755.0 in Q1 2026, and down 157.18% year-over-year from $48765.0 in Q2 2025.
Powered by 
Analysis
Nexalin Technology (NXL) Change in Receivables (2021 - 2026) Analysis & Trends
Nexalin Technology has reported Change in Receivables for 6 years, with the latest figure at -$27886.0 in Q2 2026.
- On a quarterly basis, Change in Receivables fell 157.18% year-over-year to -$27886.0 in Q2 2026; TTM through Jun 2026 was -$44724.0, a 181.07% decrease from a year earlier, with the FY2025 full-year figure at $33722.0, changed N/A from the prior year.
- Change in Receivables was -$27886.0 for Q2 2026 at Nexalin Technology, down from -$755.0 in the prior quarter.
- The five-year high for Change in Receivables was $53540.0 in Q1 2022, with the low at -$51916.0 in Q3 2025.
- Average Change in Receivables over 5 years is $645.29, with a median of -$100.0 recorded in 2024.
- The largest YoY upside for Change in Receivables was 9314.09% in 2025 against a maximum downside of 1171.76% in 2025.
- Over 5 years, Change in Receivables stood at -$5477.0 in 2022, then tumbled by 59.36% to -$8728.0 in 2023, then jumped by 155.5% to $4844.0 in 2024, then soared by 639.74% to $35833.0 in 2025, then plunged by 177.82% to -$27886.0 in 2026.
- The last three Change in Receivables figures came in at -$27886.0 (Q2 2026), -$755.0 (Q1 2026), and $35833.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 386.00 Mn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 74.90 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | -224.00 Mn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 177.00 Mn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 46.00 Mn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 10.20 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 172.10 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | -90.00 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | -27,886.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -27,886.00 |
| Mar 31, 2026 | -755.00 |
| Dec 31, 2025 | 35,833.00 |
| Sep 30, 2025 | -51,916.00 |
| Jun 30, 2025 | 48,765.00 |
| Mar 31, 2025 | 1,040.00 |
| Sep 30, 2024 | 4,844.00 |
| Jun 30, 2024 | 518.00 |
| Mar 31, 2024 | -100.00 |
| Dec 31, 2023 | -8,728.00 |
| Sep 30, 2023 | 161.00 |
| Jun 30, 2023 | 10,772.00 |
| Mar 31, 2023 | -1,325.00 |
| Dec 31, 2022 | -5,477.00 |
| Sep 30, 2022 | -13,336.00 |
| Jun 30, 2022 | -34,980.00 |
| Mar 31, 2022 | 53,540.00 |
| Dec 31, 2021 | -564.00 |